Advertisement

More on atorvastatin and fibrinogen

      It is an ongoing discussion whether atorvastatin may increase fibrinogen concentrations in patients with hyperlipidemia. In their letter to the editor Wierzbicki and collegues presumed that atorvastatin increases fibrinogen concentration in specific patient populations [

      Wierzbicki AS, Crook MA, Nair DR, Mikhailidis DP, Winder AF. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. Atherosclerosis 2000; 148: 204.

      ]. We think that this conclusion is not justified regarding the data published so far.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Wierzbicki AS, Crook MA, Nair DR, Mikhailidis DP, Winder AF. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. Atherosclerosis 2000; 148: 204.

      2. Wierzbicki AS, Lumb PJ, Sernra Y, et al. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM 1999; 92: 387–394.

      3. Marais AD, Firth JC, Bateman ME, et al. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 1527–1531.

      4. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. Effect of atorvastatin on plasma fibrinogen. Lancet 1998; 351: 569–570.

      5. Nair DR, Papadakis JA, Jagroop IA, Mikhailidis DP, Winder AF. Statins and fibrinogen. Lancet 1998; 351: 1430.

      6. Bertolotto A, Bandinelli S, Ruocco L, et al. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. Atherosclerosis 1999; 143: 455–457.

      7. Davidson M, McKenney J, Stein E, et al. For the Atorvastatin Study Group 1. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1475–1481.

      8. Jones P, Kafonek S, Laurora I, Hunninghake D. For the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol 1998; 81: 582–587.

      9. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Athyrou VV, Kontopoulos AG. Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolaemia. A pilot, randomized, double-blind, dose-titrating study. Clin Drug Invest 1998; 16: 219–227.

      10. Otto C, Geiss HC, Donner MG, Parhofer KG, Schwandt P. Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular immunoadsorption apheresis. Ther Apheresis 2000 (in press).

      11. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al., Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin in patients with hypertriglyceridemia. JAMA 1996; 275: 128–133.